Sectors

SCNI
Scinai Immunotherapeutics Ltd.
0.26
1 x 0.25
1 x 0.25
bid
ask
+
0.01
5.09%
01:24 PM
timesize
Ytd-63.76%
1y-88.88%
0.24
day range
0.25
0.21
52 week range
3.48
Open0.24Prev Close0.25Low0.24High0.25Mkt Cap323.05K
Vol76.73KAvg Vol3.71MEPS-14.23P/E-0.02Forward P/EN/A
Beta2.11Short Ratio0.09Inst. Own2.36%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg0.37200-d Avg0.771yr Est700.00

SCNI News

benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
prnewswire.com
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expan

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
prnewswire.com
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or t

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
prnewswire.com
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future o

JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
benzinga.com
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the compan

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
prnewswire.com
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Financing led by institutional life sciences investor, with participation from new and existing inve

Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
prnewswire.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structur

JERUSALEM, April 6, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai"

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
prnewswire.com
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through R

JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai" o

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
prnewswire.com
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Sp

JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharma

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
prnewswire.com
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

JERUSALEM, March 16, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI) ("Scinai"

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Up 2,371.8% in February
defenseworld.net
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Up 2,371.8% in February

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the recipient of a

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
prnewswire.com
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Diluti

JERUSALEM, March 2, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI);("Scinai" o

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
prnewswire.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Plat

JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
prnewswire.com
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collabo

JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", o

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
prnewswire.com
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at

JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest
defenseworld.net
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the target of a la

Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3%  – What’s Next?
defenseworld.net
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next?

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report)'s share price shot up

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
prnewswire.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
prnewswire.com
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
prnewswire.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Stren

JERUSALEM , Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
prnewswire.com
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for P

New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro,

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 647 companies set new 52-week lows.